India Globalization Capital, Inc. (NYSE American: IGC), a developer of cannabis-based therapies to treat a variety of life-altering conditions, this morning provided an update on compelling in vitro data compiled from genetically engineered cell lines within an Alzheimer’s disease model showing that, at varying concentrations of IGC-AD1, mitochondrial function is enhanced by 30-60 percent. “Based on our analysis of this and other previously announced compelling data, we are readying IGC-AD1 in a liquid formulation that will not cause inebriation,” Ram Mukunda, CEO of IGC, stated in the news release. “The initial commercialization will be through licensed medical cannabis dispensaries.” As noted in this morning’s update, mitochondrial dysfunction is believed to be at the apex of the Alzheimer’s pyramid, making it responsible for triggering a cascade of symptoms resulting in the devastating condition. As such, IGC-AD1’s ability to improve mitochondrial function could serve as a significant breakthrough in the treatment of Alzheimer’s, which is noted as America’s most expensive disease with its estimated annual cost of $236 billion.
To view the full press release, visit http://nnw.fm/6gldW
About IGC
IGC is engaged in the development of cannabis based combination therapies to treat Alzheimer’s, pain, nausea, eating disorders, several end points of Parkinson’s, and epilepsy in dogs and cats. IGC has assembled a portfolio of patent filings and four lead product candidates addressing these conditions. The company is based in Maryland, USA. For more information visit www.igcinc.us
More from NetworkNewsBreaks
About NetworkNewsWire
NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
For more information please visit https://www.networknewswire.com
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
NetworkNewsWire (NNW)
New York, New York
www.networknewswire.com
212.418.1217 Office
Editor@NetworkNewsWire.com
